Synthetic Biology: Will pharma sink or swim?

2 July 2018
2019_biotech_test_vial_discovery_big

Synthetic biology — a discipline derived from the convergence of biotechnology, genetic engineering, systems biology and more — is ready for its time in the sun.

Despite being a young field, beginning in earnest in the late 1990s, synthetic biology already has a significant effect on the way we live. It has given us biofuels, degradable plastics and — for better or worse — algae butter. With the advent of the Crispr-Cas9 system in 2012, it has become cheaper and easier than ever to manipulate DNA and construct artificial biological systems.

Gene therapy

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology